Eutilex eutilex.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Eutilex (유틸렉스) is a clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases. The most advanced drug candidate is an adoptive T cell therapy, 4-1BB CTL, which has finished Phase 1 clinical trials and will begin Phase 2. Other pipeline candidates in development include monoclonal antibodies, EU-101, EU-102 and EU-103.

Eutilex (유틸렉스) is a clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases. The most advanced drug candidate is an adoptive T cel...Show all

Company (Alive / Active)

Phone:

Fax:



Seoul,
South Korea

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Eutilex $18.9M Dec 8, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Eutilex Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Monoclonal antibody which specifically recognizes b cell lymphoma and use thereof Mar 05, 2015 Jan 09, 2018 Patent
Har-nds-derived stem cells, method for separating same, and use thereof Apr 28, 2015 Application